P-339 - Effect of lisdexamfetamine dimesylate on functional impairment in children and adolescents with attention-deficit/hyperactivity disorder

Abstract

IntroductionLisdexamfetamine dimesylate (LDX) is the first long-acting, prodrug stimulant, and is approved in the USA, Canada and Brazil for the treatment of attention-deficit/hyperactivity disorder (ADHD).Objectives and aimsTo evaluate the effect of LDX on functional impairment in patients with ADHD, using the Weiss Functional Impairment Rating Scale-Parent (WFIRS-P).MethodsA randomized, double-blind, placebo-controlled trial of an optimized daily dose of LDX was conducted in children and adolescents (6–17 years) with ADHD in Europe. A 4-week dose-optimization period was followed by 3-weeks of dose-maintenance. The WFIRS-P was completed at baseline, day 28 and endpoint. A decrease from base..